New Indication for YAZ(r) approved in the U.S.

Berlin - Bayer Schering Pharma AG announced today that the U.S. Food and
Drug Administration (FDA) has approved a new indication for the company's
oral contraceptive YAZ(r) (3 mg drospirenone/20 mcg ethinyl estradiol), to
treat moderate acne in women who desire an oral contraceptive for birth
control.

With this approval, YAZ becomes the first and only oral contraceptive ever
approved by the FDA for three distinct indications. YAZ received FDA
approval as an oral contraceptive in March, 2006, and as a treatment for
the emotional and physical symptoms of premenstrual dysphoric disorder
(PMDD) in October, 2006. YAZ has demonstrated statistical and clinical
significance in treating mood swings, irritability, headaches, feeling
anxious, bloating and food cravings caused by PMDD that impact a woman's
life.

"We are delighted to have received the approval for YAZ in this third
indication. Through its innovative active ingredient drospirenone, it
offers additional benefits to women who want reliable birth control," said
Phil Smits, Head of the Business Unit Womens' Healthcare at Bayer Schering
Pharma. "YAZ is the fastest growing oral contraceptive brand in the U.S. We
are convinced that through its unique features, YAZ will further strengthen
our worldwide leading market position in the field of female
contraception."

Additional information
Two multicenter, double-blind, placebo-controlled, randomized clinical
trials of over 1000 patients revealed the statistically significant
efficacy of YAZ in treating acne. In the trials, treatment with YAZ
resulted in significant reductions in total lesion counts and in
inflammatory/non-inflammatory lesion counts. Further, investigator ratings
of "clear" and "almost clear" skin as rated on the Investigator's Static
Global Assessment (ISGA) scale were nearly four times greater in the YAZ
treatment group than in the placebo group.

Bayer Health Care
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading,
innovative companies in the healthcare and medical products industry and is
based in Leverkusen, Germany. The company combines the global activities of
the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals
divisions. The Pharmaceuticals division, Bayer Schering Pharma, comprises
the following business units: Women's Healthcare, Diagnostic Imaging,
Specialized Therapeutics, Hematology/Cardiology, Primary Care, and
Oncology. Bayer HealthCare's aim is to discover and manufacture products
that will improve human and animal health worldwide. The products enhance
well-being and quality of life by diagnosing, preventing and treating
diseases.

Berlin,	January 29, 2007
fl	(2007-0035e)

Contacts:
Oliver Renner, Tel.: +49 30 468 12431
E-mail: oliver.renner@schering.de

Dr. Friederike Lorenzen, Tel.: +49 30 468 12057
E-mail: friederike.lorenzen@schering.de

Information for editors:
A photo is available for download from the "Baynews International" server
at http://www.press.bayer.com.

Forward-looking statements
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here.
These factors include those discussed in our public reports filed with the
Frankfurt Stock Exchange and with the U.S. Securities and Exchange
Commission (including Form 20-F). The company assumes no liability
whatsoever to update these forward-looking statements or to conform them to
future events or developments.